

HCV Elimination by 2030 is feasible France

PHC 2021

Stanislas Pol, MD, PhD

Université de Paris

Liver Department, Hôpital Cochin

stanislas.pol@aphp.fr




Conflicts of interest

Speaker or Board member : Janssen, Gilead, Roche, MSD, Abbvie, Biotest, Shinogui, Vivv, NovoNordisk, LFB


Grants : Gilead, Roche, MSD

2030 Viral Hepatitis Elimination plan by 2030




* Sustainable development goals

Interventions and targets




HCV epidemiology in France



¹ C Pioche, BEH 2016; ² H Razavi, J Viral Hepat 2014 ; ³ Données CNAM

Prioritization of treatments in France





AFEF calls for universal screening to overcome final barrier to hepatitis C eradication in France

Paris, 26 September 2017

Chronic hepatitis C is now the only chronic viral disease that can be cured. Recent advances in the treatment of this chronic infection lead to rapid recovery in over 95% of patients, with almost no side effects. There should be no reason why the disease cannot be eradicated, yet due to the inconsistency of hepatitis C screening in France, 75,000 patients remain unaware that they are infected. During its annual conference, to be held in Nice from 4 to 7 October, the French Association for the Study of the Liver (AFEF) will call for the introduction of universal hepatitis C screening in France.




Communiqué de presse

L'AFEF demande la mise en place du dépistage universel afin de lever le dernier obstacle à l'éradication de l'hépatite virale C en France

HCV cascade in France



Viraemic prevalence: 0.29% (0.14–0.34)



■ New infections in 2015: 5500

*SVR rate calculated using weighted average from the proportion of patients treated with interferon-based therapies (historical) versus DAAs (current standard of care). Data analysed using a disease progression Markov model. DAA: direct-acting antiviral agent; SVR: sustained virological response

HCV cascade in France



Patients receiving DAA treatment and/or interferon therapy (between January 2015 and December 2019)

N = 86,498

Patients receiving interferons 2018-19 N = 2,579
 Patients receiving interferons without a diagnosis of CHC (hospitalization or LTD) 2015-2017 N = 8,056

Diagnosis of CHC (hospitalization or LTD) and interferon therapy but with cancer N = 12 patients

CHC patients receiving DAA treatment and/or interferon therapy

N = 75,851

Patients < 18 years of age N = 159

CHC patients over 18 years of age receiving DAA treatment and/or interferon therapy



N = 75,690

Patients who received DAA treatment and/or interferon therapy before the inclusion date

N = 4,224

CHC patients with incident DAA treatment and/or interferon therapy at inclusion date

N = 71,466






France is on the track of HCV elimination

Year of elimination according to status quo in:

2017	2030	2040	2050	2050+
2019	2030	2040	2050	2050+



- 11/45 countries should succeed the 2030 elimination plan (all without fibrosis restriction for access to therapy), 5 in 2040 and 1 in 2050
- 28/45 should not achieve before ≥ 20 years

Take home messages

- HCV Elimination = a public health challenge
- Elimination goes beyond HCV Elimination (transformation of health care infrastructures)
- Issues about the place of screening and access to care
- One of the solutions = action by sub-population → micro-elimination concept and addition of micro-eliminations will help in macro-elimination